Iniekcje doszklistkowe ranibizumabu w praktyce klinicznej
Ranibizumab Intravitreal Injections in Clinical Practice
Klinika Okulistyczna Mavit w Katowicach
Kierownik: prof. dr hab. n. med. Andrzej Stankiewicz
Stowarzyszenie Zwyrodnienia Plamki Związanego z Wiekiem (AMD)
Prezes: prof. dr hab. n. med. Andrzej Stankiewicz
Summary: n pivotal trials (MARINA, ANCHOR) ranibizumab intravitreal injections were given every month with therapeutic success, on level 90% among exudative AMD patients. Real life treatment has shown necessity of looking for others solutions with lower number of injections. In later clinical investigations (PRONTO, SUSTAIN, CATT) similar results using drug after first phase (1 x per month in first 3 months) – PRN scheme were obtained. Individual regimen has become the standard of ranibizumab treatment. Similar observations we have in world literature. In time of Symposion of AMD – Warsaw October 2012, 286 polish ophthalmologists in electronic voting told, that the average number of ranibizumab injections in first year of exudative AMD treatment is 5.3.
Słowa kluczowe: postać wysiękowa AMD, leczenie anty-VEGF.
Keywords: exudative AMD, anti-VEGF therapy.